"Praha" . "Gal\u00E9n" . "Sekund\u00E1rn\u00ED dyslipid\u00E9mie (DLP), jejich\u017E zastoupen\u00ED se pohybuje mezi 30 \u2013 40 % v\u0161ech DLP jsou d\u016Fsledkem p\u016Fsoben\u00ED n\u011Bkter\u00FDch zn\u00E1m\u00FDch chorob (choroby jater a \u017Elu\u010Dov\u00FDch cest, nefropatie, ment\u00E1ln\u00ED anorexie), hormon\u00E1ln\u00EDch poruch (hypotyre\u00F3zu, androgenn\u00ED deficit, akromegalie, hyperesterinn\u00ED stavy, hyperkortikalismus, infekce z\u00E1n\u011Bty a malnutrice) nebo jsou sdru\u017Eeny s pod\u00E1v\u00E1n\u00EDm xenobiotik (beta-blok\u00E1tory, thiazidov\u00E1 diuretika, retinoidy, kortikoidy, imunosupresivn\u00ED l\u00E9\u010Dba, antipsychotika), kter\u00E9 v\u00FDznamn\u011B ovliv\u0148uj\u00ED metabolizmus lipid\u016F a LP. K fenotypick\u00E9 manifestaci LP poruchy dojde nej\u010Dast\u011Bji u jedinc\u016F geneticky predisponovan\u00FDch, u kter\u00FDch je LP porucha zhor\u0161ena druhotnou p\u0159\u00ED\u010Dinou (nap\u0159. se jedn\u00E1 o p\u0159\u00EDr\u016Fstek t\u011Blesn\u00E9 hmotnosti, nep\u0159\u00EDzniv\u00E9 zm\u011Bny p\u0159\u00EDjmu \u017Eivin, selh\u00E1n\u00ED \u010Di po\u0161kozen\u00ED ur\u010Dit\u00FDch org\u00E1n\u016F \u010Di syst\u00E9m\u016F a farmakoterapie). Je pod\u00E1na p\u0159ehled, patofyziologick\u00E9 mechanismy, klinick\u00FD obraz a l\u00E9\u010Dba nej\u010Dast\u011Bj\u0161\u00EDch sekund\u00E1rn\u00EDch DLP." . "Secondary dyslipidaemia (DLP) whose frequency ranged between 30 \u2013 40 % of all DLP is consequence of a number of disease - liver disease and biliary obstruction, renal diseases, anorexia nervosa, hormonal disorders (hypothyroidism, androgen deficiency, acromegaly, diabetes mellitus, pregnancy, eostrogens as contraceptive or replacement therapy, hypercorticalism), infectious disease, inflammation, malnutrition). Some secondary DLP are connected with ethanol abuse, or are caused by xenobiotics (beta-blockers, thiazide diuretics, retinoids, corticosterids, immunosuppressants, dioxins, chlorinated hydrocarbons, etc.). Although many of disorders above mentioned can cause DLP in their own right it is apparent that the most marked lipid and lipoproteinb abnormalities tend to occur in those individuals that have a genetic predisposition. It is stated the overview, pathophysiology, clinical manifestation, laboratory findings, as well as management of secondary dyslipidaemias."@en . . . . "286739" . . "2"^^ . "978-80-7262-676-2" . . . "RIV/00064165:_____/10:7430!RIV11-MZ0-00064165" . "Sekund\u00E1rn\u00ED dyslipid\u00E9mie (dyslipoprotein\u00E9mie)"@cs . "2"^^ . "Zeman, Miroslav" . . . . . "Sekund\u00E1rn\u00ED dyslipid\u00E9mie (DLP), jejich\u017E zastoupen\u00ED se pohybuje mezi 30 \u2013 40 % v\u0161ech DLP jsou d\u016Fsledkem p\u016Fsoben\u00ED n\u011Bkter\u00FDch zn\u00E1m\u00FDch chorob (choroby jater a \u017Elu\u010Dov\u00FDch cest, nefropatie, ment\u00E1ln\u00ED anorexie), hormon\u00E1ln\u00EDch poruch (hypotyre\u00F3zu, androgenn\u00ED deficit, akromegalie, hyperesterinn\u00ED stavy, hyperkortikalismus, infekce z\u00E1n\u011Bty a malnutrice) nebo jsou sdru\u017Eeny s pod\u00E1v\u00E1n\u00EDm xenobiotik (beta-blok\u00E1tory, thiazidov\u00E1 diuretika, retinoidy, kortikoidy, imunosupresivn\u00ED l\u00E9\u010Dba, antipsychotika), kter\u00E9 v\u00FDznamn\u011B ovliv\u0148uj\u00ED metabolizmus lipid\u016F a LP. K fenotypick\u00E9 manifestaci LP poruchy dojde nej\u010Dast\u011Bji u jedinc\u016F geneticky predisponovan\u00FDch, u kter\u00FDch je LP porucha zhor\u0161ena druhotnou p\u0159\u00ED\u010Dinou (nap\u0159. se jedn\u00E1 o p\u0159\u00EDr\u016Fstek t\u011Blesn\u00E9 hmotnosti, nep\u0159\u00EDzniv\u00E9 zm\u011Bny p\u0159\u00EDjmu \u017Eivin, selh\u00E1n\u00ED \u010Di po\u0161kozen\u00ED ur\u010Dit\u00FDch org\u00E1n\u016F \u010Di syst\u00E9m\u016F a farmakoterapie). Je pod\u00E1na p\u0159ehled, patofyziologick\u00E9 mechanismy, klinick\u00FD obraz a l\u00E9\u010Dba nej\u010Dast\u011Bj\u0161\u00EDch sekund\u00E1rn\u00EDch DLP."@cs . . "V" . . "18"^^ . "Sekund\u00E1rn\u00ED dyslipid\u00E9mie (dyslipoprotein\u00E9mie)" . "Secondary dyslipidaemia (hyperlipidaemia)"@en . "Secondary dyslipidaemia; hyperlipidaemia; liver disease; biliary obstruction; renal diseases; anorexia nervosa; hormonal disorders; pathophysiology; clinical manifestation; laboratory findings; management"@en . "Sekund\u00E1rn\u00ED dyslipid\u00E9mie (dyslipoprotein\u00E9mie)" . . . . "505"^^ . . "RIV/00064165:_____/10:7430" . "Sekund\u00E1rn\u00ED dyslipid\u00E9mie (dyslipoprotein\u00E9mie)"@cs . . . "\u017D\u00E1k, Ale\u0161" . . "Poruchy metabolismu a v\u00FD\u017Eivy" . . . . . "[F596B1A16858]" . "Secondary dyslipidaemia (hyperlipidaemia)"@en .